MedTrace Logo

Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

NCT00398463 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2011-07-01

No results posted yet for this study

Summary

This study will evaluate whether adding tirofiban, administered at high bolus dose on top of aspirin and clopidogrel will lead to a lower rate of periprocedural myocardial infarction after percutaneous coronary intervention in elective patients presenting with aspirin and/or clopidogrel resistance.

Conditions

  • Angioplasty, Transluminal, Percutaneous Coronary

Interventions

DRUG

Tirofiban

Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion

DRUG

Placebo

Saline infusion will be administered for 14-24 hours

Sponsors & Collaborators

  • Università degli Studi di Ferrara

    lead OTHER

Principal Investigators

  • Marco Valgimigli, MD, PhD · Università degli Studi di Ferrara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-07-31
Completion
2011-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398463 on ClinicalTrials.gov